Bionexus Gene Lab Stock Book Value Per Share

BGLC Stock  USD 0.35  0.01  2.94%   
BioNexus Gene Lab fundamentals help investors to digest information that contributes to BioNexus Gene's financial success or failures. It also enables traders to predict the movement of BioNexus Stock. The fundamental analysis module provides a way to measure BioNexus Gene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioNexus Gene stock.
Last ReportedProjected for Next Year
Book Value Per Share 0.55  0.28 
Tangible Book Value Per Share 0.55  0.28 
As of February 25, 2025, Book Value Per Share is expected to decline to 0.28. In addition to that, Tangible Book Value Per Share is expected to decline to 0.28.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

BioNexus Gene Lab Company Book Value Per Share Analysis

BioNexus Gene's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Book Value per Share

 = 

Common Equity

Average Shares

More About Book Value Per Share | All Equity Analysis

Current BioNexus Gene Book Value Per Share

    
  0.52 X  
Most of BioNexus Gene's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioNexus Gene Lab is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

BioNexus Book Value Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for BioNexus Gene is extremely important. It helps to project a fair market value of BioNexus Stock properly, considering its historical fundamentals such as Book Value Per Share. Since BioNexus Gene's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioNexus Gene's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioNexus Gene's interrelated accounts and indicators.
-0.20.990.940.590.770.930.950.93-0.830.910.930.890.840.920.660.950.55-0.77
-0.2-0.28-0.470.030.41-0.04-0.22-0.30.680.08-0.3-0.55-0.51-0.320.18-0.08-0.610.53
0.99-0.280.950.570.740.920.950.93-0.870.910.930.890.860.930.70.960.59-0.75
0.94-0.470.950.610.540.810.870.88-0.890.750.880.920.860.870.530.840.66-0.8
0.590.030.570.610.540.540.480.42-0.290.580.420.320.340.410.590.560.16-0.24
0.770.410.740.540.540.810.730.64-0.360.930.640.430.430.630.820.860.09-0.31
0.93-0.040.920.810.540.810.980.96-0.730.940.960.750.860.950.680.960.43-0.69
0.95-0.220.950.870.480.730.980.99-0.840.910.990.840.930.990.650.960.55-0.76
0.93-0.30.930.880.420.640.960.99-0.880.851.00.880.971.00.560.910.59-0.8
-0.830.68-0.87-0.89-0.29-0.36-0.73-0.84-0.88-0.64-0.88-0.94-0.92-0.89-0.39-0.76-0.670.84
0.910.080.910.750.580.930.940.910.85-0.640.850.650.70.850.830.980.34-0.52
0.93-0.30.930.880.420.640.960.991.0-0.880.850.880.971.00.560.910.59-0.8
0.89-0.550.890.920.320.430.750.840.88-0.940.650.880.890.870.330.760.72-0.92
0.84-0.510.860.860.340.430.860.930.97-0.920.70.970.890.970.410.80.69-0.84
0.92-0.320.930.870.410.630.950.991.0-0.890.851.00.870.970.580.910.6-0.78
0.660.180.70.530.590.820.680.650.56-0.390.830.560.330.410.580.770.18-0.06
0.95-0.080.960.840.560.860.960.960.91-0.760.980.910.760.80.910.770.47-0.65
0.55-0.610.590.660.160.090.430.550.59-0.670.340.590.720.690.60.180.47-0.61
-0.770.53-0.75-0.8-0.24-0.31-0.69-0.76-0.80.84-0.52-0.8-0.92-0.84-0.78-0.06-0.65-0.61
Click cells to compare fundamentals
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Competition

BioNexus Common Stock Shares Outstanding

Common Stock Shares Outstanding

12.07 Million

At present, BioNexus Gene's Common Stock Shares Outstanding is projected to increase significantly based on the last few years of reporting.
In accordance with the recently published financial statements, the book value per share of BioNexus Gene Lab is about 0.523 times. This is 130.76% lower than that of the Chemicals sector and 100.53% lower than that of the Materials industry. The book value per share for all United States stocks is 99.97% higher than that of the company.

BioNexus Book Value Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioNexus Gene's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioNexus Gene could also be used in its relative valuation, which is a method of valuing BioNexus Gene by comparing valuation metrics of similar companies.
0.52153.4535.350.04100%
BioNexus Gene is currently under evaluation in book value per share category among its peers.

BioNexus Gene Current Valuation Drivers

We derive many important indicators used in calculating different scores of BioNexus Gene from analyzing BioNexus Gene's financial statements. These drivers represent accounts that assess BioNexus Gene's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BioNexus Gene's important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Market Cap226.5M364.8M164.3M8.4M9.7M9.2M
Enterprise Value223.8M362.8M162.2M2.6M3.0M2.9M

BioNexus Fundamentals

Return On Equity-0.0987
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-300%-250%-200%-150%-100%-50%
Return On Asset-0.0229
Profit Margin(0.10) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-50%0%50%
Operating Margin(0.51) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-50%0%50%
Current Valuation2.62 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-50%0%50%100%
Shares Outstanding17.97 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150%100%150%200%
Shares Owned By Insiders43.72 %
Shares Owned By Institutions0.99 %
Number Of Shares Shorted313.76 K
Price To Earning350.00 X
Price To Book0.67 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Price To Sales0.70 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Revenue9.77 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%1,000%2,000%3,000%4,000%5,000%6,000%
Gross Profit1.25 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-311,000%2,000%3,000%4,000%5,000%6,000%7,000%
EBITDA(2.49 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-2,000%-1,000%0%1,000%
Net Income(2.63 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-10,000%-5,000%0%5,000%
Cash And Equivalents1.34 M
Cash Per Share0.01 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Total Debt133.4 K
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-40%-20%0%20%40%60%80%
Debt To Equity0 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%0%20%40%
Current Ratio3.84 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3120,000%40,000%60,000%80,000%100,000%
Book Value Per Share0.52 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-350,000%-300,000%-250,000%-200,000%-150,000%-100,000%-50,000%
Cash Flow From Operations(1.3 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50,000%0%50,000%100,000%150,000%
Short Ratio0.03 X
Earnings Per Share(0.06) X
Number Of Employees30
Beta1.66
Market Capitalization6.46 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-50%0%50%100%
Total Asset11.4 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%100%200%300%400%500%600%700%
Retained Earnings(1.84 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100,000%-50,000%0%50,000%100,000%
Working Capital6.42 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Net Asset11.4 M

About BioNexus Gene Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze BioNexus Gene Lab's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNexus Gene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNexus Gene Lab based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether BioNexus Gene Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNexus Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionexus Gene Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionexus Gene Lab Stock:
Check out BioNexus Gene Piotroski F Score and BioNexus Gene Altman Z Score analysis.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.95)
Earnings Share
(0.06)
Revenue Per Share
0.521
Quarterly Revenue Growth
0.03
Return On Assets
(0.02)
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.


 
News Freq…Investor S…